Are Patients with Asthma and Chronic Obstructive Pulmonary Disease Preferred Targets of COVID-19?
The coronavirus pandemic, known as coronavirus disease 2019 (COVID-19), is an infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus first identified in patients from Wuhan, China. Since December 2019, SARS-CoV-2 has spread swiftly around the world, infected more than 25 million people, and caused more than 800,000 deaths in 188 countries. Chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) appear to be risk factors for COVID-19, however, their prevalence remains controversial. In fact, studies in China reported lower rates of chronic respiratory conditions in patients with COVID-19 than in the general population, while the trend is reversed in the United States and Europe. Although the underlying molecular mechanisms of a possible interaction between COVID-19 and chronic respiratory diseases remain unknown, some observations can help to elucidate them. Indeed, physiological changes, immune response, or medications used against SARS-CoV-2 may have a greater impact on patients with chronic respiratory conditions already debilitated by chronic inflammation, dyspnea, and the use of immunosuppressant drugs like corticosteroids. In this review, we discuss importance and the impact of COVID-19 on asthma and COPD patients, the possible available treatments, and patient management during the pandemic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:84 |
|---|---|
| Enthalten in: |
Tuberculosis and respiratory diseases - 84(2021), 1 vom: 06. Jan., Seite 22-34 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bouazza, Belaid [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Asthma |
|---|
| Anmerkungen: |
Date Revised 30.03.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4046/trd.2020.0101 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316688142 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316688142 | ||
| 003 | DE-627 | ||
| 005 | 20240330233213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4046/trd.2020.0101 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1356.xml |
| 035 | |a (DE-627)NLM316688142 | ||
| 035 | |a (NLM)33099990 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bouazza, Belaid |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Are Patients with Asthma and Chronic Obstructive Pulmonary Disease Preferred Targets of COVID-19? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The coronavirus pandemic, known as coronavirus disease 2019 (COVID-19), is an infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus first identified in patients from Wuhan, China. Since December 2019, SARS-CoV-2 has spread swiftly around the world, infected more than 25 million people, and caused more than 800,000 deaths in 188 countries. Chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) appear to be risk factors for COVID-19, however, their prevalence remains controversial. In fact, studies in China reported lower rates of chronic respiratory conditions in patients with COVID-19 than in the general population, while the trend is reversed in the United States and Europe. Although the underlying molecular mechanisms of a possible interaction between COVID-19 and chronic respiratory diseases remain unknown, some observations can help to elucidate them. Indeed, physiological changes, immune response, or medications used against SARS-CoV-2 may have a greater impact on patients with chronic respiratory conditions already debilitated by chronic inflammation, dyspnea, and the use of immunosuppressant drugs like corticosteroids. In this review, we discuss importance and the impact of COVID-19 on asthma and COPD patients, the possible available treatments, and patient management during the pandemic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Asthma | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Chronic Obstructive Pulmonary Disease | |
| 650 | 4 | |a Chronic Respiratory Diseases | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Hadj-Said, Dihia |e verfasserin |4 aut | |
| 700 | 1 | |a Pescatore, Karen A |e verfasserin |4 aut | |
| 700 | 1 | |a Chahed, Rachid |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tuberculosis and respiratory diseases |d 2012 |g 84(2021), 1 vom: 06. Jan., Seite 22-34 |w (DE-627)NLM222134194 |x 1738-3536 |7 nnns |
| 773 | 1 | 8 | |g volume:84 |g year:2021 |g number:1 |g day:06 |g month:01 |g pages:22-34 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4046/trd.2020.0101 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 84 |j 2021 |e 1 |b 06 |c 01 |h 22-34 | ||